Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants
2017 · Leukemia · 320 citations
https://doi.org/10.1038/leu.2017.253
P
Peter Brossart
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
551
Papers
19.9K
Citations
75
h-index
243
i10-index
Peter Brossart is an academic researcher from University Hospital Bonn. The author has contributed to research in topics: Immunotherapy and Immune Responses & Cancer Immunotherapy and Biomarkers & Immune Cell Function and Interaction. The author has an h-index of 75, co-authored 469 publications.
ORCID: 0009-0002-9324-5527Papers by this author
worksHer-2/neu-derived peptides are tumor-associated antigens expressed by human renal cell and colon carcinoma lines and are recognized by in vitro induced specific cytotoxic T lymphocytes.
1998 · PubMed · 225 citations
Virus-mediated delivery of antigenic epitopes into dendritic cells as a means to induce CTL
1997 · The Journal of Immunology · 221 citations
https://doi.org/10.4049/jimmunol.158.7.3270
Epidemiological, genetic, and clinical characterization by age of newly diagnosed acute myeloid leukemia based on an academic population-based registry study (AMLSG BiO)
2017 · Annals of Hematology · 165 citations
https://doi.org/10.1007/s00277-017-3150-3
Determinants of survival in patients with brain metastases from cutaneous melanoma
2010 · British Journal of Cancer · 159 citations
https://doi.org/10.1038/sj.bjc.6605622
Transfection of Dendritic Cells with RNA Induces CD4- and CD8-Mediated T Cell Immunity Against Breast Carcinomas and Reveals the Immunodominance of Presented T Cell Epitopes
2003 · The Journal of Immunology · 95 citations
https://doi.org/10.4049/jimmunol.170.12.5892
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat